{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:23:28Z","timestamp":1788985408288,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,15]]},"DOI":"10.7759\/cureus.86044","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T09:50:14Z","timestamp":1749981014000},"source":"Crossref","is-referenced-by-count":4,"title":["Identifying Predictive Factors for Complete Skin Clearance at Week 52 by Deucravacitinib in Moderate-to-Severe Psoriasis: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"Yohei","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis\u2014head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen LL","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF\/IL-23\/IL-17 axis\u2014head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020, 92:e12946. 10.1111\/sji.12946","journal-title":"Scand J Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.11.007","article-title":"Chemokine receptors in the pathogenesis and therapy of psoriasis","volume":"65","author":"Mabuchi T","year":"2012","unstructured":"Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci. 2012, 65:4-11. 10.1016\/j.jdermsci.2011.11.007","journal-title":"J Dermatol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101817","article-title":"Epidermal CCR6+ \u03b3\u03b4 T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis","volume":"187","author":"Mabuchi T","year":"2011","unstructured":"Mabuchi T, Takekoshi T, Hwang ST. Epidermal CCR6+ \u03b3\u03b4 T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol. 2011, 187:5026-31. 10.4049\/jimmunol.1101817","journal-title":"J Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17532","article-title":"Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: a 52-week real-world study","volume":"52","author":"Hagino T","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: a 52-week real-world study. J Dermatol. 2025, 52:317-28. 10.1111\/1346-8138.17532","journal-title":"J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14864","article-title":"Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017","volume":"59","author":"AlQassimi S","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020, 59:566-71. 10.1111\/ijd.14864","journal-title":"Int J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17132","article-title":"Epidemiological analysis of the patients with psoriasis in Asian countries and region using the same clinical case cards between 2020 and 2022","volume":"51","author":"Tokuyama M","year":"2024","unstructured":"Tokuyama M, Fan P, Wang G, et al.. Epidemiological analysis of the patients with psoriasis in Asian countries and region using the same clinical case cards between 2020 and 2022. J Dermatol. 2024, 51:567-83. 10.1111\/1346-8138.17132","journal-title":"J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17427","article-title":"Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: a 24-week real-world study","volume":"51","author":"Hagino T","year":"2024","unstructured":"Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: a 24-week real-world study. J Dermatol. 2024, 51:1658-64. 10.1111\/1346-8138.17427","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000531420","article-title":"Quality of life benefit and clinical predictors of complete skin clearance in psoriasis: a multicenter, prospective, real-world study","volume":"239","author":"Jiang Y","year":"2023","unstructured":"Jiang Y, Li Y, Huang D, et al.. Quality of life benefit and clinical predictors of complete skin clearance in psoriasis: a multicenter, prospective, real-world study. Dermatology. 2023, 239:802-10. 10.1159\/000531420","journal-title":"Dermatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01261-6","article-title":"Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis","volume":"14","author":"Augustin M","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, et al.. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb). 2024, 14:2841-57. 10.1007\/s13555-024-01261-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda A","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al.. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors. Dermatol Ther (Heidelb). 2021, 11:1763-76. 10.1007\/s13555-021-00596-8","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.014","article-title":"TYK-ing all the boxes in psoriasis","volume":"149","author":"Schlapbach C","year":"2022","unstructured":"Schlapbach C, Conrad C. TYK-ing all the boxes in psoriasis. J Allergy Clin Immunol. 2022, 149:1936-9. 10.1016\/j.jaci.2022.03.014","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong AW","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al.. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023, 88:29-39. 10.1016\/j.jaad.2022.07.002","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for\u00a0evaluation of\u00a0TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober B","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al.. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for\u00a0evaluation of\u00a0TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023, 88:40-51. 10.1016\/j.jaad.2022.08.061","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.060","article-title":"Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis","volume":"90","author":"Blauvelt A","year":"2024","unstructured":"Blauvelt A, Rich P, Sofen H, et al.. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis. J Am Acad Dermatol. 2024, 90:775-82. 10.1016\/j.jaad.2023.11.060","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and\u00a0efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl M","year":"2024","unstructured":"Lebwohl M, Warren RB, Sofen H, et al.. Deucravacitinib in plaque psoriasis: 2-year safety and\u00a0efficacy results from the phase III POETYK trials. Br J Dermatol. 2024, 190:668-79. 10.1093\/bjd\/ljae014","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober B","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al.. Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024, 38:1543-54. 10.1111\/jdv.19925","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino T","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat. 2024, 35:2307489. 10.1080\/09546634.2024.2307489","journal-title":"J Dermatolog Treat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0204-3","article-title":"Patients\u2019 perspectives on the impact of genital psoriasis: a qualitative study","volume":"7","author":"Cather JC","year":"2017","unstructured":"Cather JC, Ryan C, Meeuwis K, et al.. Patients\u2019 perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther (Heidelb). 2017, 7:447-61. 10.1007\/s13555-017-0204-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1127","article-title":"Genital psoriasis is associated with significant impairment in quality of life and sexual functioning","volume":"72","author":"Ryan C","year":"2015","unstructured":"Ryan C, Sadlier M, De Vol E, et al.. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015, 72:978-83. 10.1016\/j.jaad.2015.02.1127","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola JF","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018, 31:e12589. 10.1111\/dth.12589","journal-title":"Dermatol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae312","article-title":"Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study","volume":"50","author":"Hagino T","year":"2024","unstructured":"Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study. Clin Exp Dermatol. 2024, 50:130-3. 10.1093\/ced\/llae312","journal-title":"Clin Exp Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae530","article-title":"Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions","volume":"50","author":"Hagino T","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions. Clin Exp Dermatol. 2025, 50:952-9. 10.1093\/ced\/llae530","journal-title":"Clin Exp Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17186","article-title":"Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: a single-center retrospective study","volume":"51","author":"Hagino T","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: a single-center retrospective study. J Dermatol. 2024, 51:649-58. 10.1111\/1346-8138.17186","journal-title":"J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17601","article-title":"Predictive factors for responders to deucravacitinib treatment in patients with psoriasis","volume":"52","author":"Hagino T","year":"2025","unstructured":"Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Predictive factors for responders to deucravacitinib treatment in patients with psoriasis. J Dermatol. 2025, 52:551-5. 10.1111\/1346-8138.17601","journal-title":"J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17617","article-title":"Real-world 52-week effectiveness of deucravacitinib in psoriasis: a stratified analysis by age and body mass index","volume":"52","author":"Hagino T","year":"2025","unstructured":"Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Real-world 52-week effectiveness of deucravacitinib in psoriasis: a stratified analysis by age and body mass index. J Dermatol. 2025, 52:663-71. 10.1111\/1346-8138.17617","journal-title":"J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193072","article-title":"Increased adipose tissue expression of IL-23 associates with inflammatory markers in people with high LDL cholesterol","volume":"11","author":"Kochumon S","year":"2022","unstructured":"Kochumon S, Hasan A, Al-Rashed F, et al.. Increased adipose tissue expression of IL-23 associates with inflammatory markers in people with high LDL cholesterol. Cells. 2022, 11:3072. 10.3390\/cells11193072","journal-title":"Cells"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.007","article-title":"Interferon-\u03b1-producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory T\u00a0cells during obesity","volume":"33","author":"Li C","year":"2021","unstructured":"Li C, Wang G, Sivasami P, Ramirez RN, Zhang Y, Benoist C, Mathis D. Interferon-\u03b1-producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory T\u00a0cells during obesity. Cell Metab. 2021, 33:1610-23.e5. 10.1016\/j.cmet.2021.06.007","journal-title":"Cell Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil SK","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, et al.. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020, 182:1158-66. 10.1111\/bjd.18333","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel K","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, et al.. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023, 37:2016-27. 10.1111\/jdv.19236","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref30","article-title":"Age-associated alteration in Th17 cell response is related to endothelial cell senescence and atherosclerotic cerebral infarction","volume":"9","author":"Li Q","year":"2017","unstructured":"Li Q, Ding S, Wang YM, et al.. Age-associated alteration in Th17 cell response is related to endothelial cell senescence and atherosclerotic cerebral infarction. Am J Transl Res. 2017, 9:5160-8.","journal-title":"Am J Transl Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374033-identifying-predictive-factors-for-complete-skin-clearance-at-week-52-by-deucravacitinib-in-moderate-to-severe-psoriasis-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T09:50:14Z","timestamp":1749981014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374033-identifying-predictive-factors-for-complete-skin-clearance-at-week-52-by-deucravacitinib-in-moderate-to-severe-psoriasis-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.86044","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,15]]}}}